(0.06%) 5 476.56 points
(-0.01%) 38 776 points
(0.02%) 17 861 points
(0.27%) $80.55
(0.82%) $2.81
(0.13%) $2 332.10
(-0.29%) $29.31
(-0.07%) $970.20
(0.02%) $0.932
(-0.16%) $10.64
(0.06%) $0.788
(-1.86%) $86.80
Live Chart Being Loaded With Signals
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders...
Stats | |
---|---|
Šios dienos apimtis | 170 627 |
Vidutinė apimtis | 0 |
Rinkos kapitalizacija | 40.85M |
EPS | $-0.310 ( Q3 | 2022-05-09 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.684 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.104 (10.40%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-02-10 | Aberman Zami | Buy | 80 616 | Common Stock |
2021-05-26 | Clover Wolf Capital - Limited Partnership | Sell | 122 663 | Common Stock |
2021-05-26 | Clover Wolf Capital - Limited Partnership | Sell | 22 015 | Common Stock |
2021-05-27 | Clover Wolf Capital - Limited Partnership | Sell | 71 775 | Common stock |
2021-05-27 | Clover Wolf Capital - Limited Partnership | Sell | 24 110 | Common stock |
INSIDER POWER |
---|
0.00 |
Last 98 transactions |
Buy: 11 245 290 | Sell: 1 084 851 |
Tūris Koreliacija
Pluristem Therapeutics Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Pluristem Therapeutics Koreliacija - Valiuta/Žaliavos
Pluristem Therapeutics Finansinės ataskaitos
Annual | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.770 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.770 |
FY | 2020 |
Pajamos: | $23 000.00 |
Bruto pelnas: | $23 000.00 (100.00 %) |
EPS: | $-1.600 |
FY | 2019 |
Pajamos: | $54 000.00 |
Bruto pelnas: | $52 000.00 (96.30 %) |
EPS: | $-2.90 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Pluristem Therapeutics
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA\'s Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.